Amarin Corp Plc (AMRN)

[Number sleven]

JRoon, Not exactly. Our composition patents would still be invalid. After you read the ruling in GSK v Teva you will probably understand. The strategy is proving that the carve out isn't successful. Both the full label and the "partial" label are for the same indication. Our lawyers haven't done that yet in Amarin v Hikma. We haven't reached the appropriate stage of the suit. When you look at GSK v Teva, you can see how they did it.
Sleven,